Tezacaftor and Ivacaftor
Brand Names: Symdeko
Methodology & AI Transparency ⓘ
Tezacaftor and Ivacaftor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage symdeko: is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence .
- 2 Real-world patient consensus: Tracked across 20 patient dosage logs with a 81% satisfaction benchmark (RxCUI 1243046).
- 3 Typical cash cost range: Dispensing cost comparison spans $130.00 mail/discount cash up to $318.50 uninsured retail (federal NADAC $3.0000).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Tezacaftor and Ivacaftor: nausea (12.4%), headache (11%), dizziness (6.7%).
Ask our AI Specialists anything about Tezacaftor and Ivacaftor
Tezacaftor and Ivacaftor Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage symdeko: is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
12.1 Mechanism of Action Tezacaftor facilitates the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of mature CFTR protein delivered to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. For ivacaftor to function CFTR protein must be present at the cell surface. Ivacaftor can potentiate the CFTR protein delivered to the cell surface by tezacaftor, leading to a further enhancement of chloride transport than either agent alone.
With Terminal t½ estimated at 10–19 hrs depending on renal/hepatic reserve (Tezacaftor and Ivacaftor) residence kinetics and F ≈ 52%–64% systemic availability after standard oral Tezacaftor and Ivacaftor administration bioavailability, Tezacaftor and Ivacaftor undergoes mixed metabolic conjugation and unchanged urinary excretion across tezacaftor and ivacaftor regimens and establishes therapeutic activity over time to peak concentration spans 1 to 4 hrs under tezacaftor and ivacaftor maintenance.
Standard adult regimens span Kit, 50 mg, 75 mg. Prescribers screen specifically against documented intolerance or hypersensitivity reaction involving tezacaftor and ivacaftor (fda prescription therapeutic agent); concurrent restricted medications flagged in section 4/7 of the tezacaftor and ivacaftor dailymed monograph (1243046), while community micro-logs most frequently note nausea (12.4% of reports), headache (11% of reports), dizziness (6.7% of reports).
Inhibiting CYP3A4 clearance during Tezacaftor and Ivacaftor therapy increases concentration-dependent adverse effects.
Assess baseline hepatic panels and interacting prescriptions when starting Tezacaftor and Ivacaftor (fda prescription therapeutic agent).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Tezacaftor and Ivacaftor (fda prescription therapeutic agent)
- Concurrent restricted medications flagged in Section 4/7 of the Tezacaftor and Ivacaftor DailyMed monograph (1243046)
Logged Side-Effect Incidence (20 Reports)
Tezacaftor and Ivacaftor Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tezacaftor and Ivacaftor)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Tezacaftor/ivacaftor in people with cystic fibrosis who stopped Tezacaftor/ivacaftor was generally safe, well tolerated, and efficacious in people ≥12 years of age with cystic fibrosis homozygous for Phe508del-CFTR with ppFEV 1 of ≥25% and. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32586736 ↗ |
Tezacaftor and Ivacaftor Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.0000/unit (~$90.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $318.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $130.00 / mo | View logs ↓ |
Tezacaftor and Ivacaftor Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tezacaftor and Ivacaftor RxNorm Concept ID | 1243046 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.0000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $318.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $130.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tezacaftor and Ivacaftor Patient Community, Cohort Filters & Dosage Logs
Cross-verified Tezacaftor and Ivacaftor (fda prescription therapeutic agent) monograph synthesizing RxNorm 1243046, openFDA FAERS signals, and $130.00–$318.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tezacaftor and Ivacaftor community threads and patient logs by age, biological sex, dosage, and treatment duration.